Dr Rabasa-Lhoret completed his medical training in Paris from 1983 to 1990 and his certification in Endocrinology in Montpellier from 1990 to 1995.
Between 1995 and 2000, he conducted a Ph.D in food science (Montpellier France and Montreal Canada), a certification in medical nutrition (Paris France) as well as a clinical over-specialization in diabetes (Montpellier France, Clinical assistant) under the supervision of both Dr J-L Chiasson (Montreal) and Louis Monnier (Montpellier).
From January 2001 to June 2002, he made a post-doctoral fellowship in Lyon (INSERM 449 and Lyon research center in nutrition France) under the supervision of Martine Laville and Hubert Vidal.
He was also webmaster of the French diabetes association website from 2001 to 2005. He is also a member of the editorial board of Diabetes and Metabolism since 2004.
In July 2002, Dr Rabasa-Lhoret was recruited as an MD in the endocrine service of the Centre Hospitalier de l’Université de Montréal (CHUM- Hotel-Dieu) as well as an assistant professor in the Nutrition department (Université de Montréal).
Since April 2004, he has been the director of the metabolic unit at Université de Montréal and now at Institut de recherches cliniques de Montréal. The metabolic unit is a fully equipped lab for precise human phenotyping, physiologic and intervention studies in the field of nutrition, diabetes, obesity and physical exercise.
Industry Expertise (4)
Areas of Expertise (5)
Three Awards for Excellence in Teaching (professional)
Awarded by the Université de Montréal in 2012, 2013 and 2014.
Centre de recherche en nutrition de Lyon: Postdoctoral Fellowship, Nutrition 2002
Montpellier, Paris and Montreal: Ph.D., Food Sciences (Specializations in Nutrition and Diabetes) 2000
Paris and Montpellier: M.D., Endocrinology, Metabolism and Nutrition 1995
- Canadian Society of Clinical Nutrition : Member
- European Society for the Study of Diabetes : Member
- Canadian Society of Endocrinology and Metabolism : Member
- Université de Montréal : Associate Professor, Department of Nutrition
- Diabète Québec : Member
- Institut de recherches cliniques de Montréal : Director, Metabolic Unit
Media Appearances (4)
Artificial Pancreas Better than Conventional Insulin Pumps for Type 1 Diabetes Treatment: Study
Tech Times online
According to Dr. Rabasa-Lhoret, the clinical trial was the first in the world to compare two configurations of an artificial pancreas. The first, the single-hormone variant, delivers insulin, while the second, the dual-hormone version of an artificial pancreas, provides both glucagon and insulin...
The Artificial Pancreas Shown to Improve the Treatment of Type 1 Diabetes
The world’s first clinical trial comparing three alternative treatments for type 1 diabetes was conducted in Montréal by researchers at the IRCM and the University of Montreal, led by endocrinologist Dr. Rémi Rabasa-Lhoret. The study confirms that the external artificial pancreas improves glucose control and reduces the risk of hypoglycemia compared to conventional diabetes treatment...
Québec Becomes First Province to Add Victoza® to the Drug Benefit Formulary* for the Treatment of Type 2 Diabetes
"An important point for type 2 diabetes management is to ensure that most patients are reaching their HbA1c goals," said Dr. Rémi Rabasa-Lhoret, MD, PhD, associate professor, Université de Montréal. "If this is not achieved through diet and exercise and the recommended first-line therapy, metformin, an anti-hyperglycemic treatment like Victoza(®) should be initiated. The Québec government's reimbursement of Victoza(®) should provide some patients with access to a treatment to better manage their diabetes."...
Artificial pancreas better treatment than pump for diabetes: study
CTV News online
“Approximately two-thirds of patients don’t achieve their target range with current treatments,” Rabasa-Lhoret explained in a statement. “The artificial pancreas could help them reach these targets and reduce the risk of hypoglycemia, which is feared by most patients and remains the most common adverse effect of insulin therapy.”...
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive proteinThe American Journal of Clinical Nutrition
We aimed to compare the effects of altering the glycemic index or the amount of carbohydrate on glycated hemoglobin (HbA1c), plasma glucose, lipids, and C-reactive protein (CRP) in T2DM patients...
The metabolically healthy but obese individual presents a favorable inflammation profileThe Journal of Clinical Endocrinology and Metabolism
The purpose of this study was to investigate the inflammatory state in obese women displaying the “metabolically healthy but obese”(MHO) phenotype. Design: We examined the metabolic characteristics of 88 obese, sedentary postmenopausal women. ...
Metabolic and body composition factors in subgroups of obesity: what do we know?The Journal of Clinical Endocrinology and Metabolism
Obesity is thought to be a heterogeneous disorder with several possible etiologies; therefore, by examining subtypes of obesity we attempt to understand obesity's heterogeneous nature. The purpose of this review was to investigate the roles of ...
Metabolic and behavioral characteristics of metabolically obese but normal-weight womenThe Journal of Clinical Endocrinology and Matabolism
A unique subset of individuals termed metabolically obese but normal weight (MONW) has been identified. These young women are potentially at increased risk for development of the metabolic syndrome despite their young age and normal body mass index. We seek to ...
Guidelines for Premeal Insulin Dose Reduction for Postprandial Exercise of Different Intensities and Durations in Type 1 Diabetic Subjects Treated Intensively With a Basal-Bolus Insulin Regimen (Ultralente-Lispro)Diabetes Care
Objective: to evaluate and validate appropriate premeal insulin dose reductions for postprandial exercises of different intensities and durations to minimize the risk of exercise-induced hypoglycemia in type 1 diabetic subjects...